Edition:
United States

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

8.10USD
15 Dec 2017
Change (% chg)

$-0.35 (-4.14%)
Prev Close
$8.45
Open
$8.45
Day's High
$8.60
Day's Low
$7.85
Volume
1,829,821
Avg. Vol
150,687
52-wk High
$20.00
52-wk Low
$3.05

Chart for

About

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic... (more)

Overall

Beta: --
Market Cap(Mil.): $299.78
Shares Outstanding(Mil.): 35.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting

Nov 07 2017

BRIEF-Calithera Biosciences Q3 operating loss per share $0.17

* Calithera biosciences reports third quarter 2017 financial results and recent highlights

Nov 02 2017

BRIEF-Calithera Biosciences files for common stock offering of up to $250 mln

* Calithera Biosciences Inc files for common stock offering of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2hHfdIt) Further company coverage:

Aug 08 2017

BRIEF-Calithera Biosciences reports Q2 operating loss per share $0.15

* Calithera Biosciences reports second quarter 2017 financial results and recent highlights

Aug 08 2017

BRIEF-Calithera Biosciences initiates randomized phase 2 combination trial of CB-839 in patients with renal cell carcinoma

* Calithera Biosciences initiates a randomized phase 2 combination trial of CB-839 in patients with renal cell carcinoma

Aug 07 2017

Earnings vs. Estimates